The Future of Medicine is Here
Imagine a world where everyone could access individualized precision therapeutics that could slow or even halt their disease and improve quality of life. At EveryONE Medicines, that is the goal we are working tenaciously toward.
Our story begins with Mila. After a happy and seemingly healthy first few years of childhood, Mila was diagnosed with a rare fatal neurodegenerative disease. In a ground-breaking race against time, Dr. Timothy Yu of Boston Children’s Hospital developed milasen, an antisense oligonucleotide targeting Mila’s unique mutation. Mila became the first person in the world to receive a medicine tailored to just one person. Since then, Mila’s mother, Julia Vitarello, has been on a mission to turn the work for Mila into a new mainstream way of solving the global crisis of rare disease in children. Julia co-founded EveryONE Medicines with the hope of creating a viable business model to bring this approach to all patients who could benefit. Together, we are working toward a future where individualized medicines are routine.
- Mila's Miracle Foundation
- Mila to More short documentary
- Milasen: The drug that went from idea to injection in 10 months
- Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
- Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives
- The quest for the era of personalised medicine
Design, develop, and manufacture individualized antisense oligonucleotide medicines on a global scale to treat life-threatening neurodegenerative diseases in children that currently have no treatment options and secure a new regulatory pathway for our individualized medicines that is sustainable with broad reimbursement from health ministries, insurance plans and health systems.
Individualized Medicines Is a Reality
We have the technology to identify the most unique genetic conditions occurring in children and design medicines to treat them–giving patients and their families a chance at a longer, healthier life.
Generating clinical evidence for individualized medicines presents a paradox because there may only be a few children across the world with a particular genetic variant which is responsible for causing their neurodegenerative disease. With this in mind, we are focused on generating clinical data in a pivotal trial that will include multiple medications treating multiple genetic variants. This is not the traditional pathway of evidence generation for regulatory approval because the traditional approach is not a viable option in a patient population this rare. Therefore, we are working closely with regulatory agencies across Europe to advance our clinical trial strategy and establish a new pathway for marketing authorization of our individualized medicines at scale.
To that end, EveryONE Medicines is honored to be serving as a pilot for the UK’s Rare Therapies Launch Pad (RTLP) working alongside multiple stakeholders, including the MHRA. Their mission is to model a scalable and sustainable system to meet the new era of individualized medicines, focused on putting in place an innovative regulatory and reimbursement end-to-end pathway to allow for rapid access to cutting-edge science by those who could benefit.
Our investment partners provide us with guidance and support as we work to achieve our vision and mission.
Meet the Team
We are experienced professionals who collaborate with each other and our extended team to change the landscape for how families help loved ones treat even the rarest of rare genetic diseases.
In his role as the CEO, Kent is responsible for driving our vision by leading the curation and collaboration of a global network of treatment centers, diagnostic firms, regulators and payers which leads to a scalable and sustainable model for individualized drug development and delivery to children affected by ultra-rare neurodegenerative diseases. Through strategic partnerships and a commitment to patient-focused innovation, he ensures the company’s transition into clinical-stage drug development will lead to the successful negotiation of new and innovative regulatory pathways for individualized medicines that will be broadly reimbursed and accessible to children in need.
Kent is a healthcare executive with 30 years of extensive experience, having held executive leadership positions with multiple top-tier pharmaceutical companies, emerging biotech firms, and as a senior executive of a national payer-owned PBM. Throughout his career, he has taken active roles in bringing disruptive solutions to the healthcare supply chain, creating a pathway for access to new medicines that address critical disease states.
His comprehensive expertise spans brand and generic pharmaceutical, specialty/infusion pharmacy, wholesale drug distribution, payor, and supply-chain leadership. Currently, Kent serves as a Venture Partner at ARCH Venture Partners and sits on the board of SlateRx. Previously, he served as the Chief Commercial Officer for EQRx, the Chief Industry Relations Officer for OptumRx (United Health Group's PBM), a Principal with Blue Fin Group (an IntegriChain company), the Global Vice President of Market Access with Acorda Therapeutics and held various leadership roles with Schering Plough and Merck. He has also served in multiple advisory roles for pharmaceutical firms, payer organizations and the National Business Group on Health.
Kent earned his MBA in International Business at Emory University's Goizueta Business School and received his BS in Business Management & Organizational Change at Indiana University's Kelley School of Business.
Founder & CEO, Mila’s Miracle Foundation
Co-founder, N=1 Collaborative
Co-founder, EveryONE Medicines
In her quest to open up the field of individualized medicines which her daughter Mila pioneered, Julia co-founded EveryONE Medicines with the aim of making individualized medicines like milasen scalable and accessible to rare disease patients world-wide. In parallel, she continues to run Mila’s Miracle Foundation, as well as co-founded the N=1 Collaborative which serves as the global scientific hub for individualized medicines.
In December 2016, Julia founded Mila's Miracle Foundation (MMF) upon learning that her seemingly healthy six-year-old daughter, Mila had Batten disease, a fatal genetic condition with no cure. In an unprecedented race against time to save her daughter, Julia’s collaboration with Dr. Timothy Yu from Boston Children’s Hospital (BCH) led to the first ever drug tailored to just one person, affectionately named milasen. After showing great promise in the first year of treatment, Mila’s disease slowly continued to progress. In February 2021, Mila’s big spirit left her little body. Driven by a sense of hope and responsibility, Julia is on a mission to turn the groundbreaking work that went into milasen into an impactful solution to the global health crisis of rare disease in children.
Julia has engaged academics, biotechs, government and foundations in this space and created a global following of Mila’s story and the potential of individualized medicines. She regularly presents at scientific meetings and conferences around the US and beyond. Through MMF, she initiated the work toward a novel gene replacement therapy trial targeting Mila’s variant of Batten (CLN7), launched a Neurodegenerative Disease Clinic at Children’s Hospital Colorado and co-runs the first single cell atlas of pediatric disease with BCH. Julia’s primary focus is now on moving “From Mila to Millions”, making individualized medicines a routine way of treating rare disease worldwide.
Lakshmi leads the company’s preclinical research and development efforts starting from mutation selection and ASO amenability to establishment of in vitro and in vivo assays for selection of a safe therapeutic candidate. She is responsible for technical assay transfer, project management, cross-site and cross-discipline coordination with CROs to ensure timely execution of preclinical studies.
Lakshmi has 20+ years of hands-on experience in the biotech space working in the field of nucleic acid-based therapeutics, including ASOs, agonists, antagonists and mRNA-based vaccines for targeting the rare neural, immune-oncology, viral, metabolic, and autoimmune diseases. She is very passionate about scientific research and finding cures to improve the lives of patients.
Prior to joining EveryONE Medicines, she worked at GeneLeap Biotechnology/Luye Life Sciences on HPV mRNA vaccines, mRNA cap analogs and novel delivery approaches for targeting multiple organs. In her previous roles at Spring Bank and Idera Pharmaceuticals, she worked on diverse projects from discovery to Phase 3 and was a part of several academic and industry collaborations.
Lakshmi earned her Ph.D. in Neuroendocrinology from the University of Delhi, India. She is a recipient of the Indian National Science Academy (INSA) Medal for Young Scientists in the field of Animal Sciences. She did her post-doctoral fellowships at Massey University, New Zealand and Harvard Medical School in the fields of neural regeneration, pancreatitis and heat shock proteins. She has co-authored over 50 publications and is listed as an inventor on 33 issued US patents.
Craig leads scientific efforts at EveryONE Medicines focused on evaluating patient amenability to antisense oligonucleotide (ASO) therapies. He designs ASOs for individual patients and applies his expertise in bioinformatics to analyze and mine large-scale biomedical data resources, contributing to the organization's mission to bring individualized genetic medicines to those in need.
Craig is a bioinformatics scientist with over a decade of experience at the intersection of genomics, neurobiology, and therapeutic development. His expertise spans single-cell DNA sequencing, cancer genomics, and the design of ASO therapeutics for rare and neurodevelopmental diseases.
Prior to joining EveryONE Medicines, Craig worked as a consultant with Third Rock Ventures and several early-stage biotech companies, helping define therapeutic strategy and identifying genetic targets amenable to ASO therapy. He trained in Peter J. Park’s lab at Harvard Medical School, where his doctoral and postdoctoral work uncovered mutational landscapes in aging neurons and pioneered new methods for analyzing single-cell sequencing data. His contributions have led to several high-impact publications and helped guide the development of treatment approaches for neurodegenerative disease.
Craig received his Ph.D. in Bioinformatics and Integrative Genomics from Harvard Medical School and holds a B.S. in Biomedical Engineering and Applied Mathematics from Johns Hopkins University. He has co-authored numerous peer-reviewed publications in Science, Nature Neuroscience, and Nature Genetics.
Sri leads the company’s scientific initiatives from gene mutation selection to first clinical administration. He manages the strategic collaborations with partners to increase and drive performance towards a scalable therapeutic development process.
Sri has over 25 years of industrial experience in drug discovery and drug development across various disease therapeutic areas including rare-oncology. Throughout his career, he led the advancement of project portfolios from early discovery through Phase 3 clinical development. He has deep knowledge in conceptualizing ASO-based therapies and managing ASO pipelines. Prior to joining EveryONE Medicines, Sri worked in scientific leadership positions at Idera Pharmaceuticals and TetraLogic Pharmaceuticals. He established and led several research and translational collaborations in the US, China, and Europe. He was also a member of the business development team and was involved in licensing clinical assets.
Sri earned his Ph.D. in Biochemistry from the University of Akron. He then did his post-doctoral fellowship at St. Jude Children’s Research Hospital in pediatric cancer and at the University of Pennsylvania in autoimmune diseases. He has co-authored 30 publications and is listed as an inventor in several U.S.-issued patents.
Operations and Administration
Barbara implements organizational programs, policies, and operating procedures to monitor operational effectiveness, support the team administratively, and make sure everyone has the tools necessary to work seamlessly.
Barbara brings over three decades of administrative experience to her role at EveryONE Medicines and has honed her skills working for senior executives at Fidelity Investments, GE Healthcare, Boston Children’s Hospital, SevOne Inc, and Triplet Therapeutics. She is skilled at holistically performing a multitude of projects, while building working relationships with external stakeholders and counterparts.
Development Operations
Deb works with the team to operationalize EveryONE Medicine’s vision. She listens to patients, discovering what is important to them to ensure that their voice is heard as we embark on the drug development process. She also liaises with internal and external groups to manage the overall strategic plan, including implementation and execution of timelines, budgets, and deliverables, and management of outsourcing partners.
She has over 25 years experience in drug development across multiple functions including clinical operations and development, regulatory affairs, quality assurance, alliance management, and outsourced vendor management. Having worked across multiple therapeutic areas, including experience with those that are orphan, rare, and ultra-rare, Deb has the skills to help our company take the next step. She also has experience in development of biologics, as well as small molecules, peptides, proteins, and antisense oligonucleotides.
Deb received her BS, Biology from University of Massachusetts Boston and is passionate about being part of medical innovations and technology on the cutting edge, especially those that help address an unmet medical need.
Michelle plays a pivotal role in shaping the company’s clinical strategy and medical direction. She oversees the development and execution of clinical trials, ensuring regulatory compliance and scientific integrity while advancing innovative therapies. Michelle collaborates with cross-functional teams, including research, regulatory, and commercial divisions, to drive the successful translation of genetic discoveries into patient treatments.
Michelle is a distinguished physician-scientist with extensive experience in neurology, clinical research, and therapeutic development. With two decades of experience in academic medicine and subsequent leadership roles in biotech, she has been instrumental in advancing innovative treatments and driving strategic initiatives to bring transformative therapies to patients.
Dr. Mellion’s career has been defined by her expertise in both academia and industry. As a faculty member at Warren Alpert Medical School of Brown University, she conducted grant-funded research, directed multiple training programs, and provided patient care at the MDA neuromuscular clinic and her private neurology practice. Transitioning to industry, she had roles of increasing responsibility at Biogen, contributing to remyelination research and the development of novel biomarkers, before co-leading the pain program at Vertex Pharmaceuticals. She later led the development of a first-in-class therapy for facioscapulohumeral muscular dystrophy (FSHD). Prior to joining EOM, Michelle served as chief medical officer at PepGen Inc. leading a cross functional team driving the clinical development of enhanced delivery oligonucleotide therapeutics for rare neuromuscular diseases.
Michelle earned her undergraduate degree with honors in molecular biology from Colgate University, followed by a medical degree from Wake Forest University School of Medicine. She completed her internship in medicine, neurology residency, and fellowship in clinical neurophysiology at Brown University. Committed to serving rare disease communities beyond industry, she continues to consult with the FSHD Society, a patient advocacy organization. Her academic research and work in industry has resulted in numerous original publications in top tier journals.
Nicole is the Head of People Operations and Administration for EveryONE Medicines. She plays a pivotal role in creating an environment where our employees are encouraged to break down barriers and achieve the impossible for our patients.
Nicole joins EveryONE Medicines with over 18 years of experience in People Operations and Administration.
Nicole started her career in the technology sector supporting the office of several CEOs in Executive Assistant and Chief of Staff roles. In these positions, she acted as a strategic thought partner and trusted advisor for Executive teams and spearheaded several operational and human resources endeavors.
Nicole pivoted into biotech in 2012 and oversaw People Operations at Intellia Therapeutics, Kymera Therapeutics and most recently at Centessa Pharmaceuticals. She is experienced in steering global People Operations’ strategies and policies in Human Resources, IT, Facilities and Administration. Nicole believes in driving people operational excellence that fosters a high-performance culture, to attract, develop and retain top talent.
Nicole received a BS in Business Administration and a Human Resource certification from Southern New Hampshire University.
Andrew supports the company by identifying the new capabilities and technologies that the team's need to deliver on the vision of EveryONE Medicines. He supports the end-to-end process from identification of the genetic mutation in the patient through to treatment and monitoring. Critical to his role is exploring opportunities to develop partnerships as well as building novel capabilities for the company.
Andrew has over 25 years of experience across academia, pharmaceutical and life science companies throughout all stages of the development and commercialization of medicines. Throughout his career he has delivered new capabilities with a focus on how Real-World Evidence and Data/Digital Strategy can change the paradigm of drug discovery and development. Prior to joining EveryONE Medicines Andrew had been CEO of Our Future Health where he defined the strategy, recruited a team of over 170 people, sourced and partnered to deliver the capabilities to execute the vision of one of recruiting one of the world’s largest prospective cohorts and genetic resources, establishing one of the fastest recruiting research programs globally.
Andrew received his DPhil in Statistic from the University of Oxford. He remained in Oxford for the following 10 years, first as a post-doctoral fellow in Infectious Disease Epidemiology, and later as a senior scientist working on the Million Women Study. He has co-authored over 100 publications and continues to serve as an advisor or board member to a number of organizations .